Palbociclib (a CDK4/6 inhibitor) is associated with a favorable progression free rate in RB expressing, CDK4 amplified well-differentiated and de-differentiated liposarcomas that experienced prior progression on systemic treatment [97]. Here, CDK4 is linked to liposarcoma.